Michael B. Miller is a partner in the New York office of Morrison & Foerster. His practice includes the representation of clients in complex litigation in federal and state courts and in investigations before federal and state regulatory agencies. Mr. Miller regularly represents clients before both the Department of Justice’s Antitrust Division and the Federal Trade Commission in connection with mergers and acquisitions, including deals in the pharmaceutical, aluminum, financial services, energy, computer software and consumer electronics industries.

Mr. Miller also represents clients in civil and commercial matters at both the trial and appellate levels. His cases have included representation of a publicly traded English investment trust in the New York Commercial Division, a large U.S. bank in U.S. antitrust litigation arising out of credit card operations, a trade association as amicus curiae in significant pending antitrust litigation action in the federal courts, a major health care provider in shareholder class actions in the Southern District of New York, the independent directors of a mutual fund group with respect to market timing cases and investigations, a large UK bank in US antitrust litigation, and an individual involved in the Arthur Andersen/Enron matter.

Mr. Miller is the Co-chair of the Corporate Counseling Committee of the ABA Antitrust Section, the Editor of The Antitrust Counselor , and speaks and writes frequently on a range of litigation and competition law matters.

• Representing Bank of America in action brought by American Express against Visa, MasterCard, and several major card-issuing banks. American Express alleges that defendants violated the Sherman Act by conspiring to exclude American Express from the card-issuing and network services markets, as well as the debit card network services market.
  
  
• Representing Lord Jacob Rothschild and RIT Capital Partners PLC in connection with litigation pending in the New York Commercial Division.
  
  
• Obtained U.S. antitrust approval for Alcan Inc., in connection with its successful takeover of Pechiney SA
  
  
• Obtained U.S. antitrust approval for Aventis in connection with its merger with Sanofi-Synthelabo.